Gilead Sciences will pay as much as $7.8 billion to acquire partner Arcellx in its largest deal since 2020, the biopharma company said on Monday, as it looks to strengthen its lineup of cancer treatm… [+2296 chars]Read More
Gilead to acquire cancer therapy developer Arcellx for up to 78 billion CNBC
